MedTrace Logo

TriPRIL CAR T Cells in Multiple Myeloma

NCT05020444 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-05-12

No results posted yet for this study

Summary

This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells.

This research study involves the study drugs:.

* TriPRIL CAR T Cells
* Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

Conditions

Interventions

DRUG

TriPRIL CAR T Cells

Intravenous infusion

DRUG

Cyclophosphamide

Intravenous infusion

DRUG

Fludarabine

Intravenous infusion

Sponsors & Collaborators

  • Marcela V. Maus, M.D.,Ph.D.

    lead OTHER

Principal Investigators

  • Matthew J Frigault, MD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-05
Primary Completion
2028-02-24
Completion
2028-02-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05020444 on ClinicalTrials.gov